Clinical trials: Cancer Related Cardiovascular Toxicity
HER2-positive Breast Cancer, Targeted Therapy
Cardiotoxicity of Targeted Therapy for HER-2 Positive Breast Cancer Patients at High Altitude
This is a prospective, multicenter, cohort study aiming to explore the cardiotoxicity of targeted therapy for HER-2 positive breast cancer patients who lives in high altitude area.
- Conditions
- HER2-positive Breast Cancer, Targeted Therapy, Cardiac Toxicity, High Altitude
- Trial name
- NCT05063643
- Testing
- High altitude
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Affiliated Hospital of Qinghai University
Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ
Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumors from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy.
- Conditions
- Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma
- Trial name
- NCT00004036
- Testing
- sargramostim, amifostine trihydrate, carboplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Cleveland Clinic
Breast Cancer, Adverse Effect of Radiation Therapy
Study to See Whether Breath-Hold Techniques During RT Are Effective in Helping to Improve Sparing of the Heart
The study hopes to determine whether patients with left-sided breast cancer are at an increased risk of cardiac changes due to radiation to the breast +/- Anthracycline-based chemotherapy +/- Herceptin and whether a deep…
- Trial name
- NCT02052102
- Testing
- Radiation therapy
- Where
- Canada
- Volunteers
- 63 people
- Sponsor
- AHS Cancer Control Alberta
Cardiac Toxicity, Lymphoma
Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00002827
- Testing
- bleomycin sulfate, filgrastim, dexrazoxane hydrochloride
- Where
- 39 sites in United States, Australia and 1 more
- Volunteers
- 294 people
- Sponsor
- Children's Oncology Group
Breast Cancer
Assessment of Cardiotoxicity After Chemotherapy for Breast Cancer by Cardio-vascular Magnetic Resonance (MR)
Consecutive patients with a first diagnosis of breast cancer will be identified at the Tom Baker Cancer Centre (TBCC) and included into the study, if they are going to receive chemotherapy with anthracyclines and / or Trastuzumab…
- Trial name
- Cardiotox (NCT00679874)
- Testing
- Cardio-vascular MRI
- Where
- Canada
- Volunteers
- 66 people
- Sponsor
- University of Calgary
Non-small Cell Lung Cancer, Cardiac Toxicity
Evaluation of Impedance Cardiography for Assessing Hemodynamic Shifts in Patients With LA-NSCLC During Treatment.
This study aimed to investigate the role of impedance cardiography (ICG) in evaluating hemodynamic changes during the 6-minute walk test (6MWT) in patients with locally advanced non-small cell lung cancer (LA-NSCLC) who underwent…
- Trial name
- NCT06277388
- Testing
- Impedance cardiography
- Where
- China
- Volunteers
- 231 people
- Sponsor
- Sun Yat-sen University
Chemotherapeutic Toxicity, Cardiotoxicity
Strategy Therapy on Cancer Therapy-Related Cardiac Dysfunction
The investigators use the cancer registration system of National Cheng Kung University Hospital to timely screen and evaluate those patients having breast cancer or lymphoma to enroll patients to participate in this clinical…
- Conditions
- Chemotherapeutic Toxicity, Cardiotoxicity, Heart Failure, Breast Cancer
- Trial name
- NCT05892146
- Testing
- Prevention therapy, Rescue therapy
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Cheng-Kung University Hospital
Hairy Cell Leukemia
US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)
This study is being conducted to satisfy a post-marketing requirement (PMR) to provide evidence characterizing 1) the safety of moxetumomab pasudotox-tdfk in patients who are 65 years of age and older and/or 2) the safety of…
- Trial name
- PROXY (NCT04125290)
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- AstraZeneca
Anthracyclines-Induced Cardiotoxicity, Cardiotoxicity
Dapagliflozin to Prevent Anthracycline-Induced Cardiotoxicity
Anthracyclines, such as doxorubicin, are effective anticancer agents but may cause dose-dependent cardiac injury, including early changes in left ventricular function and cardiac biomarkers.
- Trial name
- DAPA-AIC (NCT06888505)
- Testing
- Dapagliflozin (Forxiga)
- Where
- Iraq
- Volunteers
- 94 people
- Sponsor
- Hawler Medical University
Cardiac Toxicity, Malignant Neoplasm
MRI in Detecting Heart Damage in Patients With Cancer Receiving Chemotherapy With Exercise Capacity Addendum
This trial studies how well magnetic resonance imaging (MRI) works in detecting heart damage in patients with cancer receiving chemotherapy.
- Conditions
- Cardiac Toxicity, Malignant Neoplasm, Breast Cancer
- Trial name
- NCT01719562
- Testing
- Magnetic resonance imaging, Physical Activity, Healthy Living
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Wake Forest University Health Sciences
Mucositis, Multiple Myeloma
Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma
RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00482846
- Testing
- Palifermin, melphalan, questionnaire administration
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Breast Cancer
Breast Radiotherapy Audio Visual Enhancement for Sparing the Heart
This study investigates the Breathe Well device to test whether it is superior to the existing treatment standard of the Varian Realtime Position Management (RPM) system in assisting patients with deep inspiration breath hold.
- Trial name
- BRAVEHeart (NCT02881203)
- Testing
- Breathe Well, RPM
- Where
- Australia
- Volunteers
- 45 people
- Sponsor
- University of Sydney
Cardiac Toxicity, Acute Leukemia
Association Between Telomere Length and Cardiac Dysfunction
Compelling epidemiological evidence indicates that alterations of relative telomere length (RTL) are associated with cardiac dysfunction caused by chemotherapy in children with acute leukemia (AL).The aim of this study was to…
- Conditions
- Cardiac Toxicity, Acute Leukemia, Childhood Cancer
- Trial name
- NCT04409379
- Testing
- Relative telomere length
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Air Force Military Medical University, China
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- 2 sites in United States, Australia
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Non-small Cell Lung Cancer, Esophageal Cancer
Radiation-induced Toxicity of the Heart
Late side effects in radio(chemo)therapy [R(CH)T] pose a critical limitation to patients' overall survival and quality of life. Even though toxicities of the heart are highly relevant for patients with cancer in the thoracic…
- Conditions
- Non-small Cell Lung Cancer, Esophageal Cancer, Breast Cancer Female
- Trial name
- CorTox (NCT06986291)
- Testing
- Imaging and biomarkers
- Where
- Germany
- Volunteers
- 325 people
- Sponsor
- Technische Universität Dresden
Lymphoma, Non-Hodgkin, Hodgkin Lymphoma
Subclinical Cardio-toxicities Evaluation With Strain Rate Echocardiography After Chemotherapy and/or Mediastinal Radiotherapy in Patient With Lymphoma
Treatments-related cardiotoxicity is a critical issue in long term lymphoma survivors, particularly at young age, and its early identification is important to prevent clinically relevant cardiac events.
- Conditions
- Lymphoma, Non-Hodgkin, Hodgkin Lymphoma, Toxicity, Cardiac
- Trial name
- Cardiocare (NCT03480087)
- Where
- Italy
- Volunteers
- 118 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
Cardiac Toxicity, Early-stage Breast Cancer
Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted
This study proposes that the addition of statins reduces the treatment delays or early discontinuations secondary to cardiotoxicity in patients with Stage I-III HER2 positive breast being treated with anti-HER2 therapy.
- Trial name
- NCT05559164
- Testing
- Lipitor 40mg Tablet
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Rutgers, The State University of New Jersey
Non-small Cell Lung Cancer, Radiation Toxicity
Radiation-induced Cardiac Toxicity After Non-small Cell Lung Cancer Radiotherapy
Despite the growing interest in investigating how the radiotherapy (RT) dose to anatomical substructures of the heart links to survival, the heart substructures at risk remain poorly defined.
- Conditions
- Non-small Cell Lung Cancer, Radiation Toxicity, Cardiac Toxicity
- Trial name
- NCT04867564
- Testing
- Echocardiography
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Military Institute od Medicine National Research Institute
Heart Failure, Breast Cancer
Cardiac Toxicity in Medical Treatment of Breast Cancer
This study will describe the epidemiology including prognosis of heart failure related to treatment with anthracycline and trastuzumab for breast cancer.
- Trial name
- CaTOB (NCT02440620)
- Where
- Denmark
- Volunteers
- 45 people
- Sponsor
- Odense University Hospital
Cancer Related Cardiovascular Toxicity
Detection and Prevention of Cancer-Related Cardiovascular Toxicity Registry
This study is being done in order to assess the cardiovascular events known as cardiovascular toxicity of chemotherapy agents and radiotherapy protocols in cancer subjects to identify risk prediction, prevention and treatment of…
- Trial name
- NCT06086132
- Testing
- Prospective validation of the HFA-ICOS risk score in a subset of subjects with newly diagnosed breast cancer and undergoing treatment with anthracyclines analogues with or without radiotherapy
- Where
- 5 sites in Italy, North Macedonia and 1 more
- Volunteers
- 10,000 people
- Sponsor
- University of Bologna